In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative. AVAC, Treatment Action Group (TAG) and the IAS brought together a group to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2021, Global Investment in HIV Cure Research and Development in 2020.
Global Investment in HIV Cure Research and Development in 2020
A Situation Analysis Report on the Mobilization of Resources for Health Research & Development in Africa
This is a report commissioned by WACI Health in an effort to identify gaps, strengths and opportunities in health research funding. This aims at informing strategy and advocacy for all stakeholders committed to expanding the resources for health research and development (R&D) in Africa drawing from the experience and lessons from existing health R&D investments.
Where Is PEPFAR’s Strategy for Key Populations?
This document from Health GAP’s PEPFAR Watch is a community analysis of the success and challenges of PEPFAR’s Key Population program and recommendations for the next PEPFAR Ambassador.
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in terms of downstream product introduction needs. Stakeholders involved in early product development may also consider leveraging some of the activities included to anticipate future needs.
2021 Pipeline Report
The Treatment Action Group Pipeline Report provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV) and tuberculosis (TB).
Read the report on the Treatment Action Group website.
Evolving Designs for HIV Prevention Trials
There are more biomedical strategies available for HIV prevention than ever before. At the same time, research is continuing. Trials must be able to test new tools and meet ethical standards by providing participants with the best available prevention package.
No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities
No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities, written and informed by trans and gender-diverse (TGD) activists from Cape Town to Berlin, with support and solidarity from AVAC, offers practical and essential priorities for demonstrable and viable HIV interventions for TGD people.
This manifesto reflects the urgent need for peer-led HIV prevention research with true ownership and acceptability in TGD communities.
Also available: download the Manifesto summary for a snapshot of key recommendations
Understanding Results of the AMP Trials
The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results to learn more.
How can research ethics committees help to strengthen stakeholder engagement in health research in South Africa? An evaluation of REC documents
The authors recommend research ethics committees (RECs) amend their application forms to better ‘trigger’ researchers to thoughtfully plan sound stakeholder engagement. In the longer term, RECs’ documents should be better harmonised internally regarding their stance on stakeholder engagement.
Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19
This document is a new tool to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), this document responds to needs expressed by both researchers and advocates as the world watched COVID-19 research progress with unprecedented speed and urgency.